Genexa gains exclusive access to AFP's dental imaging devices in Canada:
This article was originally published in Clinica
Executive Summary
Genexa Medical has secured exclusive Canadian rights to market dental imaging systems developed by Elmsford, New York-based AFP Imaging's Dent-X division. Under the terms of the agreement, Genexa will market the NewTom 3-D cone beam computed tomography (CBCT) dental scanners and the EVA+ family of intraoral, dental and digital X-ray sensors to dental practices, imaging centres and hospitals throughout Canada. Genexa, of Edmonton, Alberta, was previously one of several non-exclusive Canadian distributors for Dent-X. AFP said it expects the new agreement with Genexa to generate revenues of $4m in the next 12 months from Canadian sales of the NewTom scanners and EVA dental sensors.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.